|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Similar liver transplantation survival with selected cardiac death donors and brain death donors显示文摘 | J.Dubbeld H.Hoekstra W.Farid J.Ringers R. J.Porte H. J.Metselaar A. G.Baranski G.Kazemier A. P.van den Berg B.van Hoek | 2010 | Br J Surg2010，，5： | 2 |
| 2 | Activation of hemostasis in brain dead organ donors: an observational study显示文摘 | T.LISMAN H. G. D.LEUVENINK R. J.PORTE R. J.PLOEG | 2011 | Journal of Thrombosis and Haemostasis2011，，10： | 1 |
| 3 | Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality显示文摘 | R. F.de Wilde M. G. H.Besselink I.van der Tweel I. H. J. T.de Hingh C. H. J.van Eijck C. H. C.Dejong R. J.Porte D. J.Gouma O. R. C.Busch I. Q.Molenaar | 2012 | Br J Surg2012，，3： | 1 |
| 4 | The Impact of Aprotinin on Renal Function After Liver Transplantation: An Analysis of 1043 Patients显示文摘 | N.Warnaar S. V.Mallett M. T.De Boer N.Rolando A. K.Burroughs M. W. N.Nijsten M. J. H.Slooff K.Rolles R. J.Porte | 2007 | American Journal of Transplantation2007，，10： | 1 |
| 5 | Interlaboratory variability in assessment of the model of end‐stage liver disease score显示文摘 | TonLisman YvonneVan Leeuwen JelleAdelmeijer Ilona T. A.Pereboom Elizabeth B.Haagsma Arie P.Van Den Berg Robert J.Porte | 2008 | Liver International2008，，10： | 1 |
| 6 | Evidence against a role for platelet-derived molecules in liver regeneration after partial hepatectomy in humans显示文摘Background and Aim:Blood platelets have been shown to stimulate liver regeneration after partial hepatectomy in animal models and humans,but the molecular mechanisms involved are unclear.It has been proposed that growth factors and angiogenic molecules stored within platelets drive platelet-mediated liver regeneration,but little direct evidence in support of this mechanism is available.Methods:We assessed levels of relevant platelet-derived proteins(vascular endothelial growth factor,hepatocyte growth factor,fibroblast growth factor,platelet-derived growth factor,thrombospondin,and endostatin)in platelet-rich and platelet-poor plasma taken at various perioperative time points from patients undergoing a(extended)right partial hepatectomy(n=17)or a pylorus-preserving pancreatico-duodenectomy(n=10).In addition,we collected intraoperative samples from the efferent and afferent liver veins prior to and after completion of liver resection.Twenty-four healthy controls were included to establish reference ranges for the various tests.Results and Conclusions:Although we demonstrate perioperative changes in platelet and plasma levels of the proteins assessed,the changes observed in patients undergoing partial hepatectomy largely mirror the changes observed in patients undergoing a pylorus-preserving pancreatico-duodenectomy.In addition,no change in the growth factor levels in platelet-rich plasma between afferent and efferent liver veins was observed.Thus,the absence of an intra-or postoperative consumption of platelet-derived proteins in patients undergoing partial hepatectomy argues against a role of release of these molecules in stimulation of liver regeneration.Relevance for patients:In depth knowledge of the mechanism underlying platelet-mediated liver regeneration may facilitate development of targeted therapeutic interventions for patients with failing liver regeneration,which for example may occur following a partial hepatectomy.Although the prevailing dogma is that platelet stimulate liver regeneration by release of growth factors stored within platelets,data in this manuscript argue against this mechanism and suggest other pathways to be responsible. | Marc Kirschbaum Jelle Adelmeijer Edris M.Alkozai Robert J.Porte Ton Lisman | 2016 | Journal of Clinical & Translational Research2016，2，3： | 0 |
| 7 | Randomized Trial of Ciclosporin with 2-h Monitoring vs.Tacrolimus with Trough Monitoring in Liver Transplantation:DELTA Study显示文摘Background and Aims:Previous trials comparing cyclosporine and tacrolimus after liver transplantation(LT)showed conflicting results.Most used trough monitoring for cyclosporine(C0),leading to less accurate dosing than with 2-h monitoring(C2).Only one larger trial compared C2 with tacrolimus based on trough level(T0)after LT,with similar treated biopsy-proven acute rejection(tBPAR)and graft loss,while a smaller trial had less tBPAR with C2 compared to T0.Therefore,it is still unclear which calcineurin inhibitor is preferred after LT.We aimed to demonstrate superior efficacy(tBPAR),tolerability,and safety of C2 or T0 after first LT.Methods:Patients after first LT were randomized to C2 or T0.tBPAR,patient-and graft survival,safety and tolerability were the main endpoints,with analysis by Fisher test,Kaplan-Meier survival analysis and log-rank test.Results:In intention-totreat analysis 84 patients on C2 and 85 on T0 were included.Cumulative incidence of tBPAR C2 vs.T0 was 17.7%vs.8.4%at 3 months(p=0.104),and 21.9%vs.9.7%at 6 and 12 months(p=0.049).One-year cumulative mortality C2 vs.T0 was 15.5%vs.5.9%(p=0.049)and graft loss 23.8%vs.9.4%(p=0.015).Serum triglyceride and LDL-cholesterol was lower with T0 than with C2.Incidence of diarrhea in T0 vs,C2 was 64%vs.31%(p≤0.001),with no other differences in safety and tolerability.Conclusions:In the first year after LT immunosuppression with T0 leads to less tBPAR and better patient-/re-transplant-free survival as compared to C2. | Bastian N.Ruijter Akin Inderson Aad Pvan den Berg Herold J.Metselaar Jeroen Dubbeld Maarten E.Tushuizen Robert J.Porte Wojciech Polak Danny van der Helm Marjolein van Reeven Mar Rodriguez-Girondo Bart van Hoek | 2023 | Journal of Clinical and Translational Hepatology2023，11，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员